Recently, Shenzhen St. Regis Biotechnology Co., Ltd. (hereinafter referred to as “Shenzhen St. Regis Biotechnology”) announced the completion of the Pre-B round of financing of 100 million yuan. This round was led by the old shareholder Qianhai Woying. All other original shareholders continued to follow the investment. It is understood that this round of funds is mainly used to promote the clinical trials of the company’s research pipeline and industrialization construction.
Regis Biotechnology is a biotechnology company with mRNA technology. The company is headquartered in Shenzhen, and has established research and development, production and clinical registration centers in Wuhan and Shanghai. The company owns the mRNA-related underlying technology with global independent intellectual property rights. After several years of development, it has become a vertically integrated drug research and development enterprise characterized by technological innovation and independent controllability. It can design and develop mRNA vaccines and therapeutic drugs according to clinical and druggable needs. drug.
Since its establishment, St. Regis has been developing dozens of pipelines in three major areas, covering infectious disease vaccines, tumor immunotherapy and protein replacement therapy. Since June 2022, RH109, the world’s first freeze-dried COVID-19 mRNA vaccine (Omicron strain) developed by Regis Biologics, has obtained clinical approval in the Philippines, New Zealand and Hong Kong, China, and this vaccine was selected for development shortly thereafter. Domestic special clinical research. RH109-related research and development data were published in Cell Discovery (IF: 38). RH109 adopts the LNP freeze-drying technology independently developed by St. Regis, which can effectively maintain the physical and chemical properties and biological activity of mRNA, and realize long-term storage at 2-8°C, which improves the low stability and difficulty of prevalent mRNA vaccines. Storage and transportation industry problems.
At present, St. Regis has accumulated more than 130 patents, covering various underlying technical fields in the development of mRNA drugs. St. Regis’ research and development platform can simultaneously support the product development of its infectious disease vaccines, tumor immunotherapy and protein replacement therapy.
media reports
Arterial Network Arterial Network Entrepreneurship Bangyiou
This article is transferred from: https://readhub.cn/topic/8mlHSPstneX
This site is only for collection, and the copyright belongs to the original author.